allergic rhinitis related to house dust mite allergy
Conditions
Interventions
Sublingual immunotherapy (SLIT) with house dust mite allergen during 24-26 months.
Sponsors
ARTU Biologicals Europe BV
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age: 6-18 years; 2. History of allergic rhinitis for at least one year; 3. Positive RAST for house dust mite allergy (¡Ý2+); 4. No use of nasal steroids in month before start of baseline measurements; 5. Symptom score of at least 4/12 (four nasal symptoms with scores ranging 0-3); 6. Informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe asthma; 2. Allergic sensitivity to pets, in case these are present in the family home; 3. Planned surgery of nasal cavity in the course of the study; 4. Having received immunotherapy in past three years; 5. Contraindications to sublingual immunotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean rhinitis symptom score in September-December after 2 years of SLIT / placebo. | — |
Secondary
| Measure | Time frame |
|---|---|
| (all in September-December after 2 years of SLIT/placebo, except last outcome below) 1. Proportion of symptomfree days; 2. Proportion of days without recue medication; 3. Mean eye symptom score; 4. Total symptom score; 5. Rhintis specific quality of life questionnaire (PARQLQ); 6. Overall assessment of perceived benefit by child and parent over whole period. | — |
Contacts
Public ContactH. Moed
Erasmus Medical Center, Department of General Practice, P.O. Box 1738
Outcome results
None listed